Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Earth past its safe limits for humans, scientists say
    • US Senate passes bill to end debt ceiling stand-off and avoid default
    • Eurozone inflation falls to lowest level since Russia invaded Ukraine
    • US Senate races towards final vote on debt ceiling bill
    • US House passes debt ceiling bill in crucial step to avert historic default
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • ‘Everyone will get affected’: Tesla jolts EV charging industry
      • Goldman warns of new job cuts in ‘tougher environment’ on Wall Street
      • BHP to pay $280mn after underpaying 30,000 staff for years
      • AI will create ‘more losers than winners’ even as Nvidia soars
      • Culture wars test corporate America’s commitment to Pride month
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from June 1: US retailers warn on consumer spending, SpaceX wins Pentagon contract
      • Live news: UK government has ‘squandered’ £5bn on rail dispute, says RMT
      • Rocket Internet backs away from start-up investing in tech downturn
      • Saudi Arabia expands lithium processing to supply BMW
      • UK’s pension lifeboat fund slashes equity allocation
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Beware ‘death by GPT syndrome’
      • We should stop worshipping at the altar of convenience
      • Why Wall Street is trying to shake up the 2024 race
      • How the Thatcherites lost their Brexit dream and their party
      • Apple’s mixed reality headset is a hedge against disruption
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
      • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Porsche, Bentley, Armani: Why Miami can’t build enough branded high rises
      • Bruce Springsteen battles mortality in three-hour Edinburgh show
      • The UK’s best bakeries: the readers’ picks
      • An island-hopping idyll in Sweden’s Bohuslän archipelago
      • The big thing about tiny restaurants
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Eli Lilly & Co

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Thursday, 18 May, 2023
      LexDrugs research
      Weight-loss drugs: long-term risks could blunt investors’ appetite for remedies Premium content

      Manufacturers racing to build what could be one of industry’s biggest markets must tread with care

    • Monday, 8 May, 2023
      Dementia
      Two Alzheimer’s drugs offer hope to patients after decades of waiting

      In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

    • Wednesday, 3 May, 2023
      Eli Lilly to seek US approval after Alzheimer’s drug trial success

      Clinical study results could boost patient access to new class of treatment

    • Thursday, 27 April, 2023
      Eli Lilly to seek approval of obesity drug that could disrupt weight loss market

      US pharma group’s late-stage study has shown treatment can slash body weight by nearly a sixth

    • Tuesday, 11 April, 2023
      FT News Briefing podcast10 min listen
      Rise of the Russian informer

      Corporate America faces its sharpest drop in profits since the beginning of the Covid pandemic

    • Monday, 10 April, 2023
      Eli Lilly warns EU will miss out on key drugs under planned change to patent rules

      Chief executive says draft plan to cut market exclusivity protection could make pursuing some treatments unviable

    • Wednesday, 1 March, 2023
      Drug prices
      Eli Lilly to cut price of insulin drugs by 70%

      Pharma group’s decision comes in response to US political pressure over high cost of diabetes medication

    • Monday, 16 January, 2023
      Drug prices
      US drugmakers withdraw from NHS pricing agreement as costs soar

      AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales

    • Wednesday, 28 December, 2022
      News in-depthDrugs research
      Race is on to develop new generation of weight-loss drugs

      Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions

    • Friday, 23 December, 2022
      LexDrugs research
      Medicines: triumph of science in 2022 is worth celebrating Premium content

      From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances

    • Sunday, 6 November, 2022
      Eli Lilly says some staff want to leave Indiana because of abortion ban

      Chief executive claims Republican state government ‘rushed’ process when passing sweeping restrictions

    • Monday, 31 October, 2022
      Drugs research
      Biotech begins human trials with drug discovered using AI

      Verge says ALS therapy is one of the first to be developed by a tech-enabled platform

    • Saturday, 6 August, 2022
      Eli Lilly says Indiana abortion ban will shift jobs out of its home state

      Pharmaceutical company says new legislation will hinder its ability to attract diverse talent

    • Friday, 29 April, 2022
      Lex
      Obesity treatments: hunger-suppressing drugs whet investors’ appetite Premium content

      On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets

    • Thursday, 28 April, 2022
      Drugs research
      Eli Lilly says obesity drug has similar results to weight-loss surgery

      Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker

    • Sunday, 16 January, 2022
      InterviewCovid-19 vaccines
      ‘Anti-intellectualism’ is disrupting global response to Covid, says Eli Lilly chief

      Pharma executive warns policymakers may be incapable of preparing the public for next pandemic

    • Monday, 5 July, 2021
      News in-depthPharmaceuticals sector
      Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

      Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

    • Tuesday, 9 February, 2021
      Eli Lilly CFO steps down after ‘inappropriate’ communications

      US drugmaker says independent probe was sparked by claims of a personal relationship with an employee

    • Friday, 29 January, 2021
      Coronavirus treatment
      Drugmakers try to adapt Covid treatments to mutant strains

      Studies suggest antibody therapies are less effective against new variants

    • Thursday, 14 January, 2021
      LexDrugs research
      Alzheimer’s drugs: trials and tribulations Premium content

      Failure rate has been dauntingly high but success would be hugely profitable

    • Tuesday, 10 November, 2020
      Coronavirus treatment
      Eli Lilly receives authorisation for Covid-19 antibody treatment

      US FDA gives emergency approval to bamlanivimab therapy designed to boost immune system

    • Tuesday, 13 October, 2020
      Coronavirus treatment
      Two Covid-19 drug trials halted on safety concerns

      Johnson & Johnson and Eli Lilly announce pauses in blow to hopes for pandemic remedy

    • Friday, 9 October, 2020
      LexCoronavirus treatment
      Regeneron/Eli Lilly/Covid-19: cocktail power Premium content

      Early signs are promising but there will be limits on how much the drug companies can charge

    • Wednesday, 7 October, 2020
      Coronavirus treatment
      Lilly seeks emergency approval for Covid drug

      Antibody would be one of first treatment options for patients with mild or moderate illness

    • Monday, 10 February, 2020
      Drugs research
      Roche and Eli Lilly drugs fail ‘inherited’ Alzheimer’s trial

      Setback deals another blow to most common hypothesis about causes of the disease

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In